Skip to main content

CORRECTION article

Front. Oncol.
Sec. Cancer Molecular Targets and Therapeutics
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1544394

Shimizu, Toshio et al. “First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors.”

Provisionally accepted
Toshio Shimizu Toshio Shimizu 1,2*John Powderly MD John Powderly MD 3Albiruni Ryan Abdul Razak Albiruni Ryan Abdul Razak 4Patricia LoRusso Patricia LoRusso 5Kathy Miller Kathy Miller 6Steven Kao Steven Kao 7Sarah Kongpachith Sarah Kongpachith 8Catherine Tribouley Catherine Tribouley 8Michelle Graham Michelle Graham 8Brian Stoll Brian Stoll 8Maulik Patel Maulik Patel 8Mohammad Omar Sahtout Mohammad Omar Sahtout 8Martha Blaney Martha Blaney 8Rachel Leibman Rachel Leibman 8Talia Golan Talia Golan 10,9Anthony Tolcher Anthony Tolcher 11
  • 1 National Cancer Center Research Institute (Japan), Tokyo, Japan
  • 2 Department of New Experimental Therapeutics and International Cancer New Drug Development Center, Kansai Medical University Hospital, Osaka, Japan,, Osaka, Japan
  • 3 Carolina BioOncology Institute, Huntersville, NC, United States,, Huntersville, United States
  • 4 Cancer Clinical Research Unit, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
  • 5 Cancer Center, School of Medicine, Yale University, New Haven, Connecticut, United States
  • 6 Department of Medicine, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, United State, Indianapolis, United States
  • 7 Department of Medical Oncology, Chris O’Brien Lifehouse, Camperdown, New South Wales, Australia
  • 8 AbbVie Bay Area, South San Francisco, CA, United States, San Francisco, United States
  • 9 Oncology Institute, Sheba Medical Center at Tel-Hashomer, Tel Aviv University, Tel Aviv, Israel,, Tel Aviv, Israel
  • 10 Institute of Oncology, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel,, Ramat Gan, Israel
  • 11 New Experimental Therapeutics (NEXT) Oncology, San Antonio, TX, United States, San Antonio, United States

This article is a correction to:

  1. First-in-Human Phase 1 Dose-Escalation Results With Livmoniplimab, an Antibody Targeting the GARP:TGF-ß1 Complex, as Monotherapy and in Combination With the Anti-PD-1 Antibody Budigalimab in Patients With Advanced Solid Tumors

    1. Read original article

The final, formatted version of the article will be published soon.

    Corrigendum on: Shimizu, Toshio et al. “First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors.” Frontiers in oncology vol. 14 1376551. 29 Oct. 2024, doi:10.3389/fonc.2024.1376551 Error in Figure/Table In the published article, there was an error in Figure 4B as published. The graph included incorrect labeling of the livmoniplimab dose for the patient with the deepest response (corrected from livmoniplimab 100mg to livmoniplimab 1500mg). The corrected Figure 4B and its caption appear below. Percentage change in target lesion sum diameter measurements from baseline over time per investigator assessment in response-evaluable set (efficacy-evaluable patients defined as patients who have received at least 1 dose of study drug and have either had at least 1 postdose tumor assessment or discontinued treatment due to AE, progressive disease, or death); per RECIST v1.1 and iRECIST.] (A): Livmoniplimab monotherapy (Q2W) cohorts (N=22). (B): Livmoniplimab (Q2W) and budigalimab combination therapy cohorts (N=34). → Denotes patients still on treatment. One patient did not have on-study tumor measurement data due to early death. AE, adverse event; iRECIST, modified RECIST v1.1 criteria for immune-based therapeutics; Q2W, once every 2 weeks; RECIST, Response Evaluation Criteria in Solid Tumors. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

    Keywords: Advanced solid tumors, TGF-ß1, GARP, Immunotherapy, Anti-PD-1 antibody, combination drug therapy, Investigational therapies, Tumor microenvironment (TME)

    Received: 12 Dec 2024; Accepted: 19 Dec 2024.

    Copyright: © 2024 Shimizu, Powderly MD, Abdul Razak, LoRusso, Miller, Kao, Kongpachith, Tribouley, Graham, Stoll, Patel, Sahtout, Blaney, Leibman, Golan and Tolcher. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Toshio Shimizu, National Cancer Center Research Institute (Japan), Tokyo, Japan

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.